Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial - Loibl, S; OʼShaughnessy, J; Untch, M (Lancet Oncol, 2018)